High Quality Etravirine CAS NO (269055-15-4) Available in 99% White Powder

1. Introduction to Etravirine (CAS number 269055-15-4): Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV-1 infection. With the CAS number 269055-15-4, it represents a vital component of antiretroviral therapy regimens, offering improved efficacy and resistance profiles compared to earlier NNRTIs.

2. Chemical Structure and Composition: At its molecular level, etravirine features a complex chemical structure comprising multiple functional groups and stereocenters. Its unique arrangement enables selective inhibition of HIV-1 reverse transcriptase, a key enzyme in the viral replication cycle.

3. Mechanism of Action: Etravirine exerts its antiretroviral activity by binding to the HIV-1 reverse transcriptase enzyme and inhibiting its function. Unlike first-generation NNRTIs, etravirine demonstrates greater flexibility in binding and resistance mutations, allowing for effective suppression of drug-resistant HIV strains.

4. Clinical Use and Therapeutic Indications: Etravirine is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents in treatment-experienced patients. It is administered orally as part of a multidrug regimen, typically in combination with other classes of antiretrovirals such as protease inhibitors or integrase inhibitors.

5. Pharmacokinetics and Dosage: Etravirine is well-absorbed following oral administration, with peak plasma concentrations achieved within a few hours. It exhibits dose-proportional pharmacokinetics and is metabolized primarily by cytochrome P450 enzymes in the liver. Dosage adjustments may be necessary in patients with hepatic impairment or concomitant use of certain medications.

6. Adverse Effects and Safety Considerations: Common adverse effects associated with etravirine therapy include rash, nausea, diarrhea, and headache. Severe adverse reactions, although rare, may include hepatotoxicity and hypersensitivity reactions. Close monitoring of liver function tests and clinical symptoms is recommended during treatment.

7. Drug Interactions and Contraindications: Etravirine has the potential for significant drug interactions due to its metabolism via cytochrome P450 enzymes. Concomitant use of drugs that induce or inhibit these enzymes may alter etravirine concentrations and efficacy. Certain medications may also be contraindicated due to the risk of adverse reactions or reduced therapeutic efficacy.

8. Resistance and Cross-Resistance: While etravirine offers improved efficacy against HIV strains resistant to first-generation NNRTIs, the emergence of resistance mutations remains a concern. Cross-resistance may occur with other NNRTIs and antiretroviral classes, necessitating careful selection of treatment regimens based on resistance testing and viral genotype.

9. Patient Counseling and Adherence: Patients prescribed etravirine should receive comprehensive counseling regarding the importance of adherence to therapy, potential adverse effects, and strategies for managing drug interactions. Regular follow-up visits with healthcare providers are essential to monitor treatment response and assess tolerability.

10. Future Perspectives and Research Directions: Ongoing research aims to further optimize the efficacy, safety, and tolerability of etravirine-based regimens, particularly in treatment-experienced HIV patients with multidrug-resistant virus. Additionally, investigations into novel antiretroviral agents and therapeutic strategies continue to advance the field of HIV/AIDS treatment.